neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (il)-2/il-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. the company was formerly known as aquinox pharmaceuticals, inc. and changed its name to neoleukin therapeutics, inc. in august 2019. neoleukin therapeutics, inc. was founded in 2003 and is headquartered in seattle, washington.
Company profile
Ticker
NGNE, NLTX
Exchange
Website
CEO
Jonathan G. Drachman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AQUINOX PHARMACEUTICALS (USA) INC, AQUINOX PHARMACEUTICALS, INC, Neoleukin Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Neoleukin Corp. • Aquinox Pharmaceuticals (Canada) Inc. ...
NGNE stock data
Latest filings (excl ownership)
8-K
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
22 Apr 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
18 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett
4 Mar 24
8-K
Departure of Directors or Certain Officers
21 Feb 24
S-8
Registration of securities for employees
20 Feb 24
8-K
Neurogene Announces Business Update and 2024 Outlook
5 Jan 24
8-K
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
19 Dec 23
425
Business combination disclosure
6 Dec 23
Latest ownership filings
4
Rachel McMinn
14 Mar 24
4
Christine Mikail Cvijic
14 Mar 24
4
Stuart Cobb
14 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G
Samsara BioCapital, L.P.
14 Feb 24
SC 13G
Cormorant Asset Management, LP
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.73 mm | 25.73 mm | 25.73 mm | 25.73 mm | 25.73 mm | 25.73 mm |
Cash burn (monthly) | 1.96 mm | 1.29 mm | 1.86 mm | 3.17 mm | 1.42 mm | 2.69 mm |
Cash used (since last report) | 13.41 mm | 8.82 mm | 12.69 mm | 21.67 mm | 9.73 mm | 18.40 mm |
Cash remaining | 12.32 mm | 16.91 mm | 13.04 mm | 4.07 mm | 16.00 mm | 7.34 mm |
Runway (months of cash) | 6.3 | 13.1 | 7.0 | 1.3 | 11.2 | 2.7 |
Institutional ownership, Q3 2023
28.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 31 |
Opened positions | 4 |
Closed positions | 11 |
Increased positions | 1 |
Reduced positions | 25 |
13F shares | Current |
---|---|
Total value | 13.77 bn |
Total shares | 3.65 mm |
Total puts | 0.00 |
Total calls | 3.56 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 1.22 mm | $4.82 bn |
Redmile | 582.44 k | $2.30 bn |
Adage Capital Partners GP, L.L.C. | 310.00 k | $1.22 bn |
Nantahala Capital Management | 300.00 k | $1.18 bn |
BAC Bank Of America | 231.78 k | $915.53 mm |
Vanguard | 201.54 k | $796.08 mm |
Renaissance Technologies | 163.45 k | $646.00 k |
MS Morgan Stanley | 107.67 k | $425.30 mm |
BML Capital Management | 98.66 k | $389.72 mm |
BLK Blackrock | 96.61 k | $381.62 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Mar 24 | Stuart Cobb | Common Stock | Grant | Acquire A | No | No | 0 | 20,391 | 0.00 | 20,391 |
13 Mar 24 | Stuart Cobb | Stock Option Common Stock | Grant | Acquire A | No | No | 36.06 | 34,450 | 1.24 mm | 34,450 |
13 Mar 24 | Rachel McMinn | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 36.06 | 93,282 | 3.36 mm | 93,282 |
13 Mar 24 | Christine Mikail Cvijic | Common Stock | Grant | Acquire A | No | No | 0 | 31,903 | 0.00 | 52,844 |
13 Mar 24 | Christine Mikail Cvijic | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 36.06 | 53,900 | 1.94 mm | 53,900 |
16 Jan 24 | Julie Jordan | Stock Option Common Stock | Grant | Acquire A | No | No | 32.3 | 75,000 | 2.42 mm | 75,000 |
News
William Blair Initiates Coverage On Neurogene with Outperform Rating
21 Mar 24
HC Wainwright & Co. Maintains Buy on Neurogene, Raises Price Target to $55
19 Mar 24
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $45 Price Target
5 Mar 24
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
4 Mar 24
Press releases
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
18 Mar 24
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
4 Mar 24
Neurogene to Participate in Upcoming Investor Conferences
29 Feb 24